590 related articles for article (PubMed ID: 17485423)
1. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.
Clements PJ; Roth MD; Elashoff R; Tashkin DP; Goldin J; Silver RM; Sterz M; Seibold JR; Schraufnagel D; Simms RW; Bolster M; Wise RA; Steen V; Mayes MD; Connelly K; Metersky M; Furst DE;
Ann Rheum Dis; 2007 Dec; 66(12):1641-7. PubMed ID: 17485423
[TBL] [Abstract][Full Text] [Related]
2. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis.
De Santis M; Bosello S; La Torre G; Capuano A; Tolusso B; Pagliari G; Pistelli R; Danza FM; Zoli A; Ferraccioli G
Respir Res; 2005 Aug; 6(1):96. PubMed ID: 16107215
[TBL] [Abstract][Full Text] [Related]
3. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis.
Colaci M; Sebastiani M; Giuggioli D; Manfredi A; Spagnolo P; Luppi F; Richeldi L; Ferri C
Scand J Rheumatol; 2010 Mar; 39(2):155-9. PubMed ID: 20059446
[TBL] [Abstract][Full Text] [Related]
4. Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters.
Volpinari S; La Corte R; Bighi S; Ravenna F; Prandini N; Lo Monaco A; Trotta F
Rheumatol Int; 2011 Sep; 31(9):1183-8. PubMed ID: 20352228
[TBL] [Abstract][Full Text] [Related]
5. Relationship Between Abnormalities on High-Resolution Computerized Tomography, Pulmonary Function, and Bronchoalveolar Lavage in Progressive Systemic Sclerosis.
Cakmak G; Selcuk Can T; Gundogdu S; Akman C; Ikitimur H; Musellim B; Ongen G
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Dec; 33(4):349-354. PubMed ID: 28079847
[TBL] [Abstract][Full Text] [Related]
6. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity.
Yanaba K; Asano Y; Tada Y; Sugaya M; Kadono T; Sato S
Mod Rheumatol; 2012 Sep; 22(5):668-75. PubMed ID: 22160844
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.
Giacomelli R; Valentini G; Salsano F; Cipriani P; Sambo P; Conforti ML; Fulminis A; De Luca A; Farina G; Candela M; Generini S; De Francisci A; Tirri E; Proietti M; Bombardieri S; Gabrielli A; Tonietti G; Cerinic MM
J Rheumatol; 2002 Apr; 29(4):731-6. PubMed ID: 11950014
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
Bosello SL; De Luca G; Rucco M; Berardi G; Falcione M; Danza FM; Pirronti T; Ferraccioli G
Semin Arthritis Rheum; 2015 Feb; 44(4):428-36. PubMed ID: 25300701
[TBL] [Abstract][Full Text] [Related]
11. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study.
Goldin J; Elashoff R; Kim HJ; Yan X; Lynch D; Strollo D; Roth MD; Clements P; Furst DE; Khanna D; Vasunilashorn S; Li G; Tashkin DP
Chest; 2009 Nov; 136(5):1333-1340. PubMed ID: 19892673
[TBL] [Abstract][Full Text] [Related]
12. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
[TBL] [Abstract][Full Text] [Related]
13. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring.
Savarino E; Bazzica M; Zentilin P; Pohl D; Parodi A; Cittadini G; Negrini S; Indiveri F; Tutuian R; Savarino V; Ghio M
Am J Respir Crit Care Med; 2009 Mar; 179(5):408-13. PubMed ID: 19096004
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis.
Hoffmann-Vold AM; Aaløkken TM; Lund MB; Garen T; Midtvedt Ø; Brunborg C; Gran JT; Molberg Ø
Arthritis Rheumatol; 2015 May; 67(8):2205-12. PubMed ID: 25916462
[TBL] [Abstract][Full Text] [Related]
15. [Symptoms from the internal organs of patients with systemic sclerosis in the light of selected diagnostic tests].
Sierakowska M; Sierakowski S; Doroszkiewicz H; Lewko J; Jankowiak B; Kowalczuk K; Van Damme-Ostapowicz K; Krajewska-Kułak E
Pol Merkur Lekarski; 2011 Feb; 30(176):116-20. PubMed ID: 21544981
[TBL] [Abstract][Full Text] [Related]
16. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung.
Behr J; Vogelmeier C; Beinert T; Meurer M; Krombach F; König G; Fruhmann G
Am J Respir Crit Care Med; 1996 Aug; 154(2 Pt 1):400-6. PubMed ID: 8756813
[TBL] [Abstract][Full Text] [Related]
17. Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement.
Moyssakis I; Gialafos E; Vassiliou V; Taktikou E; Katsiari C; Papadopoulos DP; Sfikakis PP
Rheumatology (Oxford); 2005 Feb; 44(2):251-4. PubMed ID: 15546962
[TBL] [Abstract][Full Text] [Related]
18. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Paliogianni F; Sirinian C; Yiannopoulos G; Andonopoulos AP
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S17-22. PubMed ID: 22244622
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.
Kowal-Bielecka O; Kowal K; Rojewska J; Bodzenta-Lukaszyk A; Siergiejko Z; Sierakowska M; Sierakowski S
Ann Rheum Dis; 2005 Sep; 64(9):1343-6. PubMed ID: 16100339
[TBL] [Abstract][Full Text] [Related]
20. Interstitial lung disease in systemic sclerosis.
Bussone G; Mouthon L
Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]